Predictors of response to fesoterodine in patients with an overactive bladder
- 58 Downloads
An analysis has been conducted of the predictors of the fesoterodine treatment response for female patients with overactive bladder (OAB) syndrome. Eighty-seven women diagnosed with OAB and who had undergone 12 weeks of treatment with fesoterodine (4 mg/day) were involved. Prior to treatment, the patients were evaluated through their medical history, physical examinations, urine analysis, urine cultures, voiding diaries and urodynamic studies. The voiding diaries and personal interviews concerning urinary symptoms were analyzed 12 weeks after treatment. Seventy-nine (82.3%) women experienced improvement of OAB symptoms (Improvement group), and for seventeen (17.7%) women the symptoms remained unchanged or worsened (Persistence group) after treatment. In the urodynamic studies, detrusor overactivity was noted in 37 (46.8%) patients of the improvement group and 3 (17.6%) of the persistence group. The number of patients who showed detrusor overactivity in urodynamic studies before the treatment was significantly larger in the improvement group. Maximum detrusor pressure and detrusor pressure at maximum flow were higher in the persistence group but not to statistically significant levels. In pre-treatment voiding diaries, the number of urgencies per day was significantly larger in the improvement group. The efficacy of fesoterodine treatment for female OAB problems was found to be be associated with the frequency of urgency and detrusor overactivity. Thus, both voiding diaries and urgency/detrusor symptom records may aid in predicting the efficacy of fesoterodine treatment.
KeywordsFesoterodine Overactive bladder Women
We express our deep appreciation to Dr. Jack M. Harrowfield who has kindly improved the English of our manuscript.
- 6.Ellsworth, P., Berriman, S.J., Brodsky, M.: Fesoterodine: a new agent for treating overactive bladder. Amer. J. Managed Care. 15, 4 (2009)Google Scholar
- 20.Kelleher, C.J., Reese, P.R., Pleil, A.M., Okano, G.J.: Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care 8, S608–S615 (2002)Google Scholar
- 23.Kim, U.H., Kim, Y.H., Kim, M.E.: The prevalence and quality of life of overactive bladder and urinary incontinence in young women. Korean J. Urol. 45, 543–550 (2004)Google Scholar
- 25.Milsom, I., Stewart, W., Thuroff, J.: The prevalence of overactive bladder. Amer. J. Manag. Care. S565–S573 (2000)Google Scholar
- 27.Elving, L.B., Foldspang, A., Lam, G.W., Mommsen, S.: Descriptive epidemiology of urinary incontinence in 3, 100 women age 30–59. Scand. J. Urol. Nephrol. Suppl. 125, 37–43 (1989)Google Scholar
- 32.Braverman, A.S., Ruggieri, M.R.Sr.: Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Amer. J. Physiol. Regul. Integr. Comp. Physiol. 285, R701–R708 (2003)Google Scholar